Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 10, 2025Journal of Ophthalmic Inflammation and InfectionOpen Access

Efficacy and safety of fluocinolone acetonide intravitreal implant (0.2 µg/day) in patients with post-surgical inflammation associated with macular edema: a case series study

View Full Paper
Ask AI
Bookmark
Share

Authors

MMMaria MadeiraACAna CabugueiraHUHelena Urbano

Discussion

Loading...

Member takes

Overview

Case series demonstrated significant improvements in visual acuity and macular edema, suggesting FAc implants can effectively treat refractory conditions.

Key Points

  • The fluocinolone acetonide implant significantly improved mean best-corrected visual acuity over 36 months.
  • 62.5% of patients gained at least 15 letters in visual acuity without any worsening compared to baseline.
  • Cystoid macular edema showed significant reduction from baseline measures, indicating effective anatomical improvement.
  • Intraocular pressure remained stable throughout the study, highlighting a favorable safety profile for the treatment.

Cite This Study

Madeira et al. (2025) studied this question.

synapsesocial.com/papers/68c1c64554b1d3bfb60f29e5https://doi.org/10.1186/s12348-025-00503-8
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Use of intravitreal fluocinolone acetonide implant in inflammatory macular oedema2026 · 1 citations
  2. 2Real-life results after the administration of a single 0.19 mg fluocinolone acetonide (ILUVIEN®) implant in patients with refractory diabetic macular edema2024
  3. 3Fluocinolone acetonide implant in diabetic macular edema: sustained benefits and effects of following prior therapy2026
  4. 4Intravitreal fluocinolone acetonide implant for diabetic macular edema – 2-year results from IDEAL, a prospective German observational study2026
  5. 5Improvement in visual outcomes in diabetic macular edema through the reduction of macular thickness fluctuations using the 0, 19 mg fluocinolone acetonide implant2026